Background: Cardiac amyloidosis (CA) and hypertrophic cardiomyopathy (HCM) present significant diagnostic challenges due to their phenotypic overlap, with both conditions commonly manifesting as increased ventricular wall thickness and diastolic dysfunction. Accurate differentiation is critical as prognostic implications and therapeutic strategies differ significantly. Case report: We describe the case of a 65-year-old male initially diagnosed with non-obstructive HCM, presenting with syncope and exercise-induced non-sustained ventricular tachycardia (NSVT). Despite a confounding clinical presentation mimicking classical sarcomeric HCM, a systematic diagnostic evaluation revealed key "red flag" features including low-voltage ECG findings, pseudonecrosis, and a history of bilateral carpal tunnel surgery, raising suspicion of infiltrative cardiomyopathy. Further investigations, including cardiac magnetic resonance imaging, demonstrated diffuse subendocardial late gadolinium enhancement and elevated T1/T2 mapping values, strongly suggestive of CA. Technetium-99m scintigraphy confirmed transthyretin amyloidosis (ATTR), and genetic testing excluded pathogenic variants associated with sarcomeric HCM and hereditary ATTR. Targeted therapy with tafamidis and a mineralocorticoid receptor antagonist was initiated, while the initial indication for implantable cardioverter-defibrillator implantation was reconsidered based on the updated diagnosis and current guidelines. At 18-month follow-up, the patient remains clinically stable, with preserved functional capacity, normal NT-proBNP levels, and no adverse events. Conclusion: This case underscores the importance of a systematic diagnostic approach in differentiating CA from HCM, particularly in the presence of characteristic clinical and imaging findings. Early recognition and treatment of CA with disease-modifying therapies can alter its trajectory, highlighting the need for increased clinical suspicion and integration of advanced diagnostic modalities in similar cases.

Don't raise your white flag facing a sea of red ones: when cardiac amyloidosis mimics hypertrophic cardiomyopathy / G. Grilli, M. Mapelli, L. Tassetti, M. Contini, A. Baggiano, S. Gili, A. Del Torto, R. Maragna, F. Celeste, G. Sinagra, G. Pontone, P. Agostoni. - In: ESC HEART FAILURE. - ISSN 2055-5822. - (2026). [Epub ahead of print] [10.1093/eschf/xvaf029]

Don't raise your white flag facing a sea of red ones: when cardiac amyloidosis mimics hypertrophic cardiomyopathy

M. Mapelli;A. Baggiano;A. Del Torto;R. Maragna;G. Pontone;P. Agostoni
Ultimo
2026

Abstract

Background: Cardiac amyloidosis (CA) and hypertrophic cardiomyopathy (HCM) present significant diagnostic challenges due to their phenotypic overlap, with both conditions commonly manifesting as increased ventricular wall thickness and diastolic dysfunction. Accurate differentiation is critical as prognostic implications and therapeutic strategies differ significantly. Case report: We describe the case of a 65-year-old male initially diagnosed with non-obstructive HCM, presenting with syncope and exercise-induced non-sustained ventricular tachycardia (NSVT). Despite a confounding clinical presentation mimicking classical sarcomeric HCM, a systematic diagnostic evaluation revealed key "red flag" features including low-voltage ECG findings, pseudonecrosis, and a history of bilateral carpal tunnel surgery, raising suspicion of infiltrative cardiomyopathy. Further investigations, including cardiac magnetic resonance imaging, demonstrated diffuse subendocardial late gadolinium enhancement and elevated T1/T2 mapping values, strongly suggestive of CA. Technetium-99m scintigraphy confirmed transthyretin amyloidosis (ATTR), and genetic testing excluded pathogenic variants associated with sarcomeric HCM and hereditary ATTR. Targeted therapy with tafamidis and a mineralocorticoid receptor antagonist was initiated, while the initial indication for implantable cardioverter-defibrillator implantation was reconsidered based on the updated diagnosis and current guidelines. At 18-month follow-up, the patient remains clinically stable, with preserved functional capacity, normal NT-proBNP levels, and no adverse events. Conclusion: This case underscores the importance of a systematic diagnostic approach in differentiating CA from HCM, particularly in the presence of characteristic clinical and imaging findings. Early recognition and treatment of CA with disease-modifying therapies can alter its trajectory, highlighting the need for increased clinical suspicion and integration of advanced diagnostic modalities in similar cases.
Cardiac amyloidosis; Cardiomyopathies; Heart failure; Hypertrophic Cardiomyopathy; Red flags
Settore MEDS-07/B - Malattie dell'apparato cardiovascolare
2026
gen-2026
Article (author)
File in questo prodotto:
File Dimensione Formato  
do not raise.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Licenza: Creative commons
Dimensione 633.63 kB
Formato Adobe PDF
633.63 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1221319
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex 0
social impact